Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- UBS -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (9)	12/6/2002 7:17:42 PM
From: Icebrg	Read Replies (1) \| Respond to of 19

>>Gitkin could be right on the ball, for all we know.>> I am not disputing that. Not at all. He might very well be right. But he should not say BUY with a target of 18 one month and then change it to 4-6 the next, when the only fact supporting the change evidently is some anecdotal report from a clinician. As an experienced biotech analyst he should have good enough understanding about how this kind of trial is structured and as an employee at UBS Warburg he should not act as a rumor monger. A little more than a year ago he claimed, that the technology had been validated by Lilly's entering into a cooperation for the very same drug he has now - based on anecdotal reports - declared a failure. I have nothing against analysts who are skeptical with regard to anti-sense (or anything else) until it has been proven that the technology in question works and is approvable. But I don't like this flip-flopping of his. How is he "ever" going to be able to issue a recommendation with a straight face again. His customers should ask: If this is the flip - what will the flop look like? And when will it hit us? Erik